Comera Investor Presentation Deck slide image

Comera Investor Presentation Deck

SQore Well-Positioned vs. Other Approaches SQore technology does not alter the structure or physical form of antibodies in solution, reducing drug product development uncertainty, time and expense vs. some other approaches ● ● Score approach TM SQore excipients do not bind to antibody No structural or chemical change to antibody Antibody remains as a true solution with no particulates No expected impact to mAb absorption or distribution after SQ administration ● ● ● Comera LIFE SCIENCES Other viscosity reduction approach examples Alteration of protein conformation or chemistry (e.g. dehydration, resuspension) Alteration of delivered solution (e.g. non- aqueous microparticle suspension) Impact to mAb absorption or distribution after SQ administration potentially unknown Approaches that either alter mAb structure/function or the physical form of the antibody itself raise new scientific issues that may increase development risk, cost and timeline 6
View entire presentation